cardiac mesoderm enhancer-associated non-coding RNAGenealiases: CARMEN · MIR143HG
Q-omics provides the consensus-scored CARMN profile across patient tissues and cancer cell-line models. CARMN expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CARMN is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, CARMN RNA expression shows 20,793 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, BLCA, and BRCA as cancer lineages where CARMN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CARMN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CARMN survival associations across molecular data types. CARMN RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CARMN RNA expression–survival associations across cancer types. High CARMN expression shows unfavorable associations in KIRP, UVM, BLCA and LUSC, but favorable associations in LIHC and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CARMN RNA expression.
This table summarizes CARMN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for CARMN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CARMN shows lower tumor expression in BLCA, KICH, KIRP, COAD, LUSC and BRCA. The BLCA box plot shows higher CARMN RNA expression in normal versus tumor tissue (log2 FC = −2.147, t-test p < 0.001).
This table shows molecular features associated with CARMN in patient tissues and cancer cell lines. In patient samples, CARMN shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
